Ovulation women

Chronic use of combination agents depresses ovarian function. Follicular development is minimal, and corpora lutea, larger follicles, stromal edema, and other morphologic features normally seen in ovulating women are absent. The ovaries usually become smaller even when enlarged before therapy. 

Pregnanediol, 5-B-pregnane-3-a,20-ci-diol, is a major metabolite of progesterone excreted in the urine. The cyclical fluctuations in the urinary excretion of pregnanediol observed in normal ovulating women reflect changes in the secretion by the ovaries. 

Ovulation is considered a hostile event to the ovarian epithelium, making it more susceptible to damage and cancer. Interventions or conditions that limit the number of ovulations in a woman s reproductive history will have a protective effect. For instance, multiparity would decrease the number of ovulations. 

Typically, 400 follicles will mature and fully ovulate during an average woman s reproductive lifetime. The remaining 99.98 per cent of her follicles begin to develop, but regress due to inadequate FSH stimulation. The molecular detail of how FSH (and FH) promotes follicular growth is described in the main body of the text. 

The crypsis is further enhanced by there being a responsive element to ovulation. From about day 5 of the menstrual cycle, ovulation seems to be on hold while the woman meets and assesses males, including perhaps collecting sperm (Clark and Zarrow 1971 Jochle 1975 Baker 1996). This phase may last anything from 2-21 days. Depending on events during this phase ovulation may or may not occur. It seems particularly likely to occur a couple of days after the female has a brief opportunity to collect sperm from an attractive male. 

Use after childbirth - Women who elect not to breast-feed should start contraceptive therapy with the norelgestromin/ethinyl estradiol transdermal patch no sooner than 4 weeks after childbirth. If a woman begins using the patch postpartum and has not yet had a period, consider the possibility of ovulation and conception occurring prior to use of the patch, and instruct her to use an additional method of contraception (eg, condoms, spermicide, diaphragm) for the first 7 days. 

Use after abortion or miscarriage - After an abortion or miscarriage that occurs in the first trimester, the patch may be started immediately. An additional method of contraception is not needed if the patch is started immediately. If use of the patch is not started within 5 days following a first trimester abortion, the woman should follow the instructions for a woman starting the patch for the first time. In the meantime, advise her to use a nonhormonal contraceptive method. Ovulation may occur within 10 days after an abortion or miscarriage. 

Gonadotropins are used to treat infertility in women with potentially functional ovaries who have not responded to other treatments. The therapy is designed to simulate the normal menstrual cycle as far as is practical. A common protocol is daily injections of menotropins for 9 to 12 days, until estradiol levels are equal to that in a normal woman, followed by a single dose of hCG to induce ovulation. Two problems with this treatment are risks of ovarian hyperstimulation and of multiple births. Ovarian hyperstimulation is characterized by sudden ovarian enlargement associated with an increase in vascular permeability and rapid accumulation of fluid in peritoneal, pleural, and pericardial cavities. To prevent such occurrences, ovarian development is monitored during treatment by ultrasound techniques and by measurements of serum levels of estradiol. 

A loss of primary oocytes will irreversibly affect a woman s fecundity, but this is difficult to measure directly. Reproductive dysfunction can be studied by the evaluation of irregularities of menstrual cycles and onset of menarche and menopause. However, menstrual cyclicity and onset of menopause and menarche are affected by many parameters, such as age, genetics, nutritional status, stress, exercise, certain drugs and the use of contraceptives that alter endocrine feedback. The length of the menstrual cycle, particularly the follicular phase (before ovulation), can vary between individuals and may make it difficult to measure significant effects in groups of women (Burch et al., 1967 Treloar et al., 1967). 

Medroxyprogesterone acetate is given in a relatively high dose for hormonal contraception and acts primarily by inhibiting ovulation. However, as with the other progestogen-only contraceptives, other mechanisms probably play a very significant role. It is extremely effective, with less than one pregnancy per 100 woman-years. 

A 32-year-old woman who was not obese developed benign intracranial hypertension in association with ovarian hyperstimulation syndrome after ovulation induction using goserelin, follitropin, and human chorionic gonadotropin (hCG) (3). The syndrome did not recur during a second pregnancy in which follitropin and hCG were not used... 

A previously healthy 34-year-old woman who underwent ovulation induction with leuprorelin acetate and FSH developed abdominal ascites due to OHSS, followed by acute aphasia and right hemiparesis (76). The stroke was caused by a large intracardiac thrombus. 

Gonadorelin is administered intravenously, 5 pg every 90 minutes from a portable pump. The woman is followed carefully with serum estradiol levels, and an ovarian ultrasound examination is done weekly before refilling the GnRH pump. When an ovarian follicle reaches 14 mm in diameter, ovulation is induced with hCG, 5000 units subcutaneously, and the luteal phase is maintained with hCG, 1500 units every 3 days for 12 days. 

Human chorionic gonadotropin stimulates production of gonadal steroid hormones. The interstitial and corpus luteal cells of the female produce progesterone, and the Leydig cells of the male produce testosterone. hCG can be used to mimic a midcycle LH surge and trigger ovulation in a hypogonadotropic woman. 

If a woman who is receiving a dopamine agonist is late in having her menses, a pregnancy test is necessary if she is amenorrheic, pregnancy tests should be performed regularly because ovulation may occur before menstruation resumes. 

Also, in a program of timed intercourse, intrauterine insemination, and cup insemination of donor semen following ovulation induction, a significant lower number of women beyond the age of 40 became pregnant or had live births (P6). Beyond the age of 44, no woman became pregnant. 

In the course of a reproductive life of approximately 40 years, about 500 ovulations will have occurred in the average woman. The end of the reproductive phase of life, menopause, usually occurs around the age of 45-55 years. 

A The elevated level of ethynylestradiol, a synthetic estrogen, fools the pituitary gland into thinking a woman is pregnant, so ovulation does not occur. 

The combination is conveniently started on the first day of the cycle (first day of menstruation) and continued for 21 days (this is immediately effective, inhibiting the first ovulation). It is followed by a period of 7 days when no pill is taken, and during which bleeding usually occurs. Thereafter, regardless of bleeding, a new 21-day course is begun, and so on, i.e. active tablets are taken daily for 3 weeks out of 4. For easy compliance, some combined pills are packaged so that the woman takes one tablet every day without interruption (21 active then 7 dummy). 

The primary problem in studying human reproduction is that many aspects of the reproductive process occur without the knowledge of either the woman or her physician. Ovulation, fertilization, and implantation all occur as concealed events. Reproductive biologists and epidemiologists, however, have recently developed new and incisive tools to associate exposures to reproductive health. While it will be years... 

---